Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 3/20 | 0.62 |
| ▸ | RPA1 | P27694 | 3/20 | 0.50 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.48 |
| ▸ | BCL2 | P10415 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714804 | 0.84 | MARS1 (0.67) | MARS1RPA1PPP1CAMDM2MCL1 | |
| SCHEMBL6453503 | 0.83 | ALDH1A1 (0.53) | MARS1MDM2MCL1BCL2ALDH1A1 | |
| SCHEMBL8591058 | 0.83 | RPA1 (0.73) | MARS1RPA1PPP1CAMDM2MCL1 | |
| SCHEMBL6454128 | 0.81 | MARS1 (0.44) | MARS1SMN1; SMN2SLC16A3 | |
| SCHEMBL6448871 | 0.78 | NPSR1 (0.46) | MARS1RPA1PPP1CAMDM2MCL1 | |
| SCHEMBL5517694 | 0.78 | MARS1 (0.57) | MARS1RPA1PPP1CAMDM2MCL1 | |
| SCHEMBL6454699 | 0.78 | ALDH1A1 (0.55) | MARS1ALDH1A1MEN1KMT2A | |
| SCHEMBL117374 | 0.77 | MARS1 (1.00) | MARS1RPA1L3MBTL1 | |
| SCHEMBL27668789 | 0.77 | MARS1 (0.53) | MARS1RPA1PPP1CAMDM2L3MBTL1 | |
| SCHEMBL14995555 | 0.76 | MARS1 (0.64) | MARS1RPA1PPP1CAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MARS1 2921/4885RPA1 4472/4885PPP1CA 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.